Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.

To quantify mortality rates for patients successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals and compare these rates with those of the general population. Population based cohort study. British Columbia, Scotland, and England (England cohort consists of patients with cirrhosis only). 21 790 people who were successfully treated for hepatitis C in the era of interferon-free antivirals (2014-19). Participants were divided into three liver disease severity groups: people without cirrhosis (pre-cirrhosis), those with compensated cirrhosis, and those with end stage liver disease. Follow-up started 12 weeks after antiviral treatment completion and ended on date of death or 31 December 2019. Crude and age-sex standardised mortality rates, and standardised mortality ratio comparing the number of deaths with that of the general population, adjusting for age, sex, and year. Poisson regression was used to identify factors associated with all cause mortality rates. 1572 (7%) participants died during follow-up. The leading causes of death were drug related mortality (n=383, 24%), liver failure (n=286, 18%), and liver cancer (n=250, 16%). Crude all cause mortality rates (deaths per 1000 person years) were 31.4 (95% confidence interval 29.3 to 33.7), 22.7 (20.7 to 25.0), and 39.6 (35.4 to 44.3) for cohorts from British Columbia, Scotland, and England, respectively. All cause mortality was considerably higher than the rate for the general population across all disease severity groups and settings; for example, all cause mortality was three times higher among people without cirrhosis in British Columbia (standardised mortality ratio 2.96, 95% confidence interval 2.71 to 3.23; P<0.001) and more than 10 times higher for patients with end stage liver disease in British Columbia (13.61, 11.94 to 15.49; P<0.001). In regression analyses, older age, recent substance misuse, alcohol misuse, and comorbidities were associated with higher mortality rates. Mortality rates among people successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals are high compared with the general population. Drug and liver related causes of death were the main drivers of excess mortality. These findings highlight the need for continued support and follow-up after successful treatment for hepatitis C to maximise the impact of direct acting antivirals.

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the Medical Research Foundation for the submitted work; the following financial relationships, which might have an interest in the submitted work in the previous three years: STB has received consulting fees and/or honorariums from Falk, Gilead, Abbvie, and Intercept; AB has received honorariums from Gilead Sciences; HT has received honorariums from Abbvie, Gilead Sciences, Eisai, Terumo, and Fujifilm WAKO; NZJ has received honorariums from Gilead and Abbvie; PCH has received honorariums from Falk, Ferring, Gore, Lundbeck, and Norgine; he has participated on advisory boards for Abbvie BMS, Eisai, Ferring, Gilead, Janssen, MSD, Novartis, and ONO; WLI has received research funding from Gilead Sciences and Jansen-Cilag and consulting fees/honorariums from Gilead Sciences and Roche Diagnostics; SB has received grants/contracts from Gilead Sciences and consulting fees/honorariums from Abbvie, Gilead Sciences; JFD has received honorariums from Gilead Sciences, Abbvie, and MSD; KA has received honorariums and/or consulting fees from Aligos, Assembly, Arbutus, BMS, BI, Bluejay, Gilead, GSK, Janssen, Roche, Saigmet, and Sobil; he has participated on the advisory board for DrugFarm; MA has received honorariums from Gilead Sciences; EB has consulted for Roche, Astrazeneca, and Vaccitech; she has received honorariums for education events and manuscript writing with Roche, and has patents relating to vaccines against hepatitis B, hepatitis C, and liver imaging; she owns shares in Perspectum diagnostics in liver imaging. No other relationships or activities that could appear to have influenced the submitted work.